Clinical Research Directory
Browse clinical research sites, groups, and studies.
Revolade Tablets Specified Drug-use Survey
Sponsor: Novartis Pharmaceuticals
Summary
This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).
Official title: Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)
Key Details
Gender
All
Age Range
6 Years - 17 Years
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2024-07-17
Completion Date
2028-10-31
Last Updated
2026-02-19
Healthy Volunteers
No
Conditions
Interventions
eltrombopag
This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
Locations (17)
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Toyoake, Aichi-ken, Japan
Novartis Investigative Site
Chiba, Chiba, Japan
Novartis Investigative Site
Amagasaki, Hyōgo, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Matsumoto, Nagano, Japan
Novartis Investigative Site
Shimajiri-Gun, Okinawa, Japan
Novartis Investigative Site
Izumi, Osaka, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Sakai, Osaka, Japan
Novartis Investigative Site
Saitama, Saitama, Japan
Novartis Investigative Site
Ohtsu, Shiga, Japan
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Ōta-ku, Tokyo, Japan
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan
Novartis Investigative Site
Wakayama, Wakayama, Japan